Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
01:09pm, Thursday, 07'th Jul 2022
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
04:05pm, Tuesday, 05'th Jul 2022
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
01:13pm, Tuesday, 05'th Jul 2022
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:45am, Friday, 01'st Jul 2022
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Biotech Stocks That Could Make You Richer
06:45am, Sunday, 26'th Jun 2022
These two companies have moved in opposite directions this year.
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
01:55pm, Wednesday, 22'nd Jun 2022
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
01:07pm, Friday, 17'th Jun 2022
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
12:47pm, Thursday, 09'th Jun 2022
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
4 Supercharged Growth Stocks Billionaires Can't Stop Buying
09:21am, Wednesday, 08'th Jun 2022 The Motley Fool
Successful money managers piled into these fast-growing companies in the first quarter.
4 Supercharged Growth Stocks Billionaires Can't Stop Buying
05:21am, Wednesday, 08'th Jun 2022
Successful money managers piled into these fast-growing companies in the first quarter.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
01:45pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
02:10pm, Friday, 27'th May 2022 Zacks Investment Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
3 Stocks That Could Make You a Fortune Over the Next 10 Years
11:05am, Saturday, 21'st May 2022 The Motley Fool
They have one key common denominator.
3 Stocks That Could Make You a Fortune Over the Next 10 Years
07:05am, Saturday, 21'st May 2022
They have one key common denominator.
